High-Risk Neuroblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

High-Risk Neuroblastoma Market Outlook

Thelansis’s “High-Risk Neuroblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential High-Risk Neuroblastoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

High-Risk Neuroblastoma Overview

Neuroblastoma stands as the most prevalent cancer in children below the age of one and constitutes the primary solid tumor found outside the central nervous system across all age brackets. Its clinical behavior encompasses a wide range, delineated into three risk groups: low, medium, and high. Approximately 50% of neuroblastoma cases fall into the high-risk category, determined by age, disease extent, histological findings, and cytogenetic characteristics such as MYCN amplification and DNA ploidy. Notably, children over 18 months with metastatic disease are classified as high-risk due to historically poor outcomes in this subgroup. MYCN amplification also places patients in the high-risk category, except those with L1 MYCN amplified disease undergoing complete resection. The management of high-risk neuroblastoma poses significant challenges and necessitates a comprehensive approach involving multiple modalities. The treatment protocol encompasses chemotherapy, surgical resection, high-dose chemotherapy with autologous stem cell rescue, radiation therapy, immunotherapy, and isotretinoin. The duration of the current treatment regimen spans approximately 18 months. In a significant development, as of December 2023, the Food and Drug Administration has approved eflornithine (IWILFIN, USWM, LLC) to mitigate the risk of relapse in both adult and pediatric patients grappling with high-risk neuroblastoma (HRNB).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: